A new study led by researchers at The University of Texas MD Anderson Cancer Center provides a deeper understanding of the evolution of the tumor microenvironment during gastric cancer progression.
FDA delays assessment of BMS and 2seventy’s CAR-T therapy
Share this article Abecma was approved as a fifth-line therapy for relapsed or refractory multiple myeloma by the FDA in 2021. Image Credit: JHVEPhoto /